Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

>Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients

 

PARIS, August 30, 2010 /PRNewswire-FirstCall/ --

- First Results From the TEMSO Phase III Trial to be Presented During the ECTRIMS Congress in October 2010

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial. Both the 7mg and 14mg doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) or TEAEs leading to treatment discontinuation in the treatment arms versus placebo.

Effects on other clinical and MRI related outcomes further support the primary outcome. The safety profile was in line with previous clinical experience.

The TEMSO trial is the first study of a large phase III clinical development program to produce results on teriflunomide as monotherapy. Study findings from TEMSO will be presented during the platform presentation scheduled for October 15, 2010, starting at 9:15 a.m. CET at the 26th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden. The TEMSO study results are embargoed until this oral presentation
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... . , Electrical ... a new kind of building block for digital integrated ... be based on three-dimensional arrangements of nanometer-scale magnets instead ... semiconductor industry CMOS fabrication of silicon chips ... the University of Notre Dame are exploring "magnetic computing" ...
(Date:9/30/2014)... , Sept. 30, 2014 Report ... segments with highest potential revenues Do you want ... report gives you revenue predictions for those biological ... those therapies you find financial data, R&D trends, ... you get sales forecasts to 2024 at overall ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... solopack Gold cells reduce the time and effort needed ... Amy Duncan Bruce,Jerpseth Alan Greener ,Stratagene ... , strain* in an easy-to-use, single-reaction format ... 9 transformants/g of,supercoiled DNA or the competent efficiency ...
... purification from a more versatile vector , ... ,Epitope Tagging in E. coli , Katherine Felts ... ,Stratagene , Stratagene has improved the Affinity ... vector. This new E. coli cloning and expression,vector ...
... data with the MutaTrak electronic notebook , G. ... Hamovitch Doug Schroeder ,Solana Consulting Group, Solana Beach, ... record Big,Blue transgenic rodent ... entered in a logical order and updated easily,as an ...
Cached Biology Technology:XL10-Gold Cells Supplied in New Single-Reaction Format 2XL10-Gold Cells Supplied in New Single-Reaction Format 3XL10-Gold Cells Supplied in New Single-Reaction Format 4High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 2High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 3High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 4High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 5High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 6High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 7High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 8Organize Your Data from the Big Blue Mutation Assay 2Organize Your Data from the Big Blue Mutation Assay 3
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... have marine biologists come to learn about the eye-opening characteristics ... bones of whale carcasses. With each new study, scientists ... Osedax , a genus of mouthless and gutless "bone worms" ... In the latest finding, scientists at Scripps Institution of Oceanography ...
... pilot study suggest that a virtual patient advocate (VPA) ... healthier pregnancies. Developed at Boston University School of Medicine ... is an innovative tool developed to deliver preconception care ... The study results, which are published online ...
... University professorsDavid Heeger, Joseph LeDoux, and Ruth Nussenzweighave been ... D.C.-based organization announced today. Heeger and LeDoux, ... and Department of Psychology, and Nussenzweig, a professor in ... were among the 84 new members and 21 foreign ...
Cached Biology News:Bizarre bone worms emit acid to feast on whale skeletons 2Virtual patient advocate delivers preconception care to improve pregnancy outcomes 2Virtual patient advocate delivers preconception care to improve pregnancy outcomes 33 NYU faculty elected to National Academy of Sciences 2
...
Antibody Diluent for IHC 125 ml...
Sold individually or included in the MasterAmp™ PCR Optimization Kit without ammonium sulfate. Includes dNTPs, buffer, and varying amounts of MgCl2 and the MasterAmp™ PCR Enhancer (with be...
QPRT Antibody...
Biology Products: